Sierra Oncology, Inc. Common Stock
SRRA
SRRA was delisted on the 30th of June, 2022.
44 hedge funds and large institutions have $48M invested in Sierra Oncology, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 7 closing their positions.
232% more capital invested
Capital invested by funds: $14.4M → $48M (+$33.6M)
129% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 7
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
22% more funds holding
Funds holding: 36 → 44 (+8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
+$8.61M |
| 2 |
DM
Deerfield Management
New York
|
+$5.53M |
| 3 |
O
OrbiMed
New York
|
+$5.38M |
| 4 |
PA
Perceptive Advisors
New York
|
+$5.38M |
| 5 |
NLVP
New Leaf Venture Partners
New York
|
+$3.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$298K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$212K |
| 3 |
Goldman Sachs
New York
|
-$59K |
| 4 |
JP Morgan Chase
New York
|
-$39.9K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$38.5K |
SRRA Hedge Fund Activity: Q1 2017 in Review
44 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q1 2017, worth a combined $48M — up 232% from $14.4M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new SRRA positions and 7 closed out — a net gain of 9 holders — while 9 added to existing stakes and 7 trimmed.
The largest buyer was Frazier Management, adding an estimated $8.61M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $298K sold.
- 44 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q1 2017, up from 36 in Q4 2016.
- Funds reported $48M of Sierra Oncology, Inc. Common Stock stock for Q1 2017, up 232% quarter-over-quarter.
- 16 funds opened new Sierra Oncology, Inc. Common Stock positions in Q1 2017 and 7 closed out, a net change of +9 holders.
- The largest Sierra Oncology, Inc. Common Stock buyer in Q1 2017 was Frazier Management, an estimated $8.61M added.
- The largest Sierra Oncology, Inc. Common Stock seller in Q1 2017 was Baker Bros. Advisors, an estimated $298K sold.
Based on aggregated 13F filings for Q1 2017.